Skip to content

Freenome

US · FRNM #2882 by market cap Listed 2024
16.03 -0.33 -2.02%
Live - 5344 symbols - heartbeat 93s ago · 2026-10-08 07:56
Pre-market 15.93 -0.63%
After-hours 16.03 0.00%
Market cap
1.72B
P/B
-1.24
EPS
-2.39
Reader sentiment Are you bullish or bearish on FRNM?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio -1.26 Cheap vs history 6th percentile
5-year average 0.48
P/E ratio -6.85 Cheap vs history 6th percentile
5-year average -3.10 · forward -9.96
P/S ratio 57.81 Expensive vs history 95th percentile
5-year average 26.13 · forward 12.84 · #41 of 43 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Freenome (FRNM) 1.72B -6.71 -1.24 0.00%
Thermo Fisher Scientific (TMO) 244.79B 35.63 4.65 0.27%
Danaher (DHR) 153.60B 38.81 2.92 0.66%
Natera (NTRA) 57.02B -293.01 31.30 0.00%
Agilent Technologies (A) 47.67B 33.35 6.47 0.60%
Waters (WAT) 42.84B 110.38 2.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value20.75 Economic moatNarrow UncertaintyVery High

Trading 29.4% below Morningstar's fair value estimate.

Fair value

Freenome Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 21% discount to our quantitative fair value estimate of $20.75 per share; however, caution is warranted due to this estimate's very high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.8 lies in the top 20% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be cheap.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 1.7%, for example, ranks in the bottom 10% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages.

By Quantitative Equity Report

Quote time 2026-10-08 07:56:09 · For reference only, not investment advice and not tailored to your situation.